Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF

Human Reproduction

Volumn 16, Issue 8, 2001, Pages 1671-1675

  Fujii, Shunsaku ^a   Sato, Shigemi ^a   Fukui, Atsushi ^a   Kimura, Hidetaka ^a   Kasai, Goichiro ^a   Saito, Yoshiharu ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

GnRH agonist; Implantation; IVF; Ovarian stimulation; Pregnancy

Indexed keywords

BUSERELIN ACETATE; CHORIONIC GONADOTROPIN; DYDROGESTERONE; ESTRADIOL; FERTINORM P; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE; UROFOLLITROPIN;

ADULT; ARTICLE; BIRTH; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; NIDATION; OOCYTE TRANSPORT; OVULATION INDUCTION; PREGNANCY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034882547     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.8.1671     Document Type: Article

References (28)

1. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization
2. No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist
3. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?
4. Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: The influence of long and short regimens on pregnancy rates
5. Delay of gonadotropin stimulation in patients receiving gonadotropin-releasing hormone agonist (GnRH-a) therapy permits increased clinic efficiency and may enhance in vitro fertilization (IVF) pregnancy rates
6. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responders undergoing in vitro fertilization
7. Administration of a gonadotropin-releasing hormone agonist during pregnancy: Follow-up of 28 pregnancies exposed to triptoreline
8. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders
9. A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization
10. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist densentization for controlled ovarian hyperstimulation
11. Exposure to LHRH agonists in early pregnancy following the commencement of mid-luteal buserelin for IVF stimulation
12. Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality
13. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone- releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
14. Effects of chorionic GnRH analogue administration on gonadotrophin and alpha subunit secretion in post-menopausal women
15. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program
16. Immaturity and aneuploidy in human oocytes after different stimulation protocols
17. Gonadotrophin-releasing hormone agonist administered throughout the luteal phase and early pregnancy increases fecundity in IVF-embryo transfer patients (abstract). 14th Annual meeting of the ESHRE, Gothenburg
18. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout menstrual cycle
19. The role of gonadotrophin-releasing hormone in murine preimplantation embryonic development
20. Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotrophin-releasing hormone: Implications in early human implantation
21. The significance of delayed suppression using buserelin acetate and recombinant follicle-stimulating hormone in a long protocol in vitro fertilization program
22. The influence of inadvertent intranasal buserelin administration in early pregnancy
23. The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: Experience from three centres
24. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate
25. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization
26. Is long-protocol gonadotropin releasing hormone agonist administration superior to the short protocol in ovarian stimulation for in vitro fertilization?
27. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction
28. Interval required for gonadotropin-releasing hormone-agonist-induced down regulation of the pituitary in cynomolgus monkeys and duration of the refractory state